Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy
Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a number of apoptosis-induction approaches are available, site-specific delivery of therapeutic agents still remain the biggest hurdle in achieving the desired cancer treatment benefit. Additionally, sy...
Main Authors: | Suman Bishnoi, Ritudhwaj Tiwari, Sharad Gupta, Siddappa N. Byrareddy, Debasis Nayak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-02-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/10/2/90 |
Similar Items
-
The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
by: Janine Kimpel, et al.
Published: (2018-03-01) -
Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector
by: Guodong Liu, et al.
Published: (2021-08-01) -
Untargeted Lipidomics of Vesicular Stomatitis Virus-Infected Cells and Viral Particles
by: Katherine E. Havranek, et al.
Published: (2021-12-01) -
Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP
by: Saskia V. Vijver, et al.
Published: (2023-01-01) -
The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
by: Emmanuel Heilmann, et al.
Published: (2019-10-01)